Morgan Stanley Emerging Markets Debt Fund (MSD) news
Recent news
MRC/UVRI & LSHTM Uganda research unit - Uganda launches phase I clinical study of Bundibugyo virus disease vaccine
The MRC/UVRI & LSHTM Uganda Research Unit has initiated a phase I clinical trial for a Bundibugyo virus disease vaccine, marking a significant step in the global response to the ongoing outbreak. This development follows a collaborative effort between CEPI and Hilleman Laboratories, a joint venture…
AInvest Wire · 6d agoMSD says subcutaneous formulation of PD-1 inhibitor pembrolizumab approved in China - Statement
Merck & Co. (NYSE: MRK), through its global brand MSD, announced that the subcutaneous formulation of pembrolizumab, marketed as Keytruda in the United States and under the MSD brand in other regions, has received regulatory approval in China. The subcutaneous formulation offers an alternative…
AInvest Wire · Sep 29, 2026Fitch affirms MSD investment at 'BBB-'; outlook stable
Fitch Ratings has affirmed the credit rating of MSD Investment Corp. at 'BBB-', with a stable outlook, reflecting the company’s strong credit fundamentals and diversified investment portfolio. The rating agency highlighted MSD’s $4.9 billion investment portfolio, which is predominantly composed of…
AInvest Wire · Jun 22, 2026BDT & MSD in talks to sell old post office property: WSJ
The U.S. General Services Administration (GSA) is in negotiations to sell the Old Post Office building on Pennsylvania Avenue in Washington, D.C., a historic property that once housed the Trump International Hotel. The GSA aims to transfer the property out of federal ownership as part of its…
AInvest Wire · Jun 10, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.